Heart surgery blood filter shows kidney protection promise in new analysis

NCT ID NCT06781294

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study re-analyzes data from a previous trial of 343 heart surgery patients who received a blood purification device (oXiris) connected to the heart-lung machine. The original trial found a 12% reduction in acute kidney injury within 7 days. Now researchers will examine how the filter affects antibiotics, heparin, and other drugs, and whether certain patient groups benefit more. The goal is to better understand the device's safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Extracorporeal cytokine hemadsorption device (oXiris)
What this could lead to
If successful, this analysis could clarify how best to use blood purification during heart surgery to protect kidneys and guide safe antibiotic dosing.
What could go wrong
This is a post-hoc analysis of an already completed trial, not a new experiment. Findings may be less reliable and need confirmation in future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Universitat de Barcelona

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.